These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 29627275)

  • 1. Growth impairment in mucopolysaccharidoses.
    Melbouci M; Mason RW; Suzuki Y; Fukao T; Orii T; Tomatsu S
    Mol Genet Metab; 2018 May; 124(1):1-10. PubMed ID: 29627275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failures of Endochondral Ossification in the Mucopolysaccharidoses.
    Jiang Z; Byers S; Casal ML; Smith LJ
    Curr Osteoporos Rep; 2020 Dec; 18(6):759-773. PubMed ID: 33064251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucopolysaccharidosis IVA and glycosaminoglycans.
    Khan S; Alméciga-Díaz CJ; Sawamoto K; Mackenzie WG; Theroux MC; Pizarro C; Mason RW; Orii T; Tomatsu S
    Mol Genet Metab; 2017; 120(1-2):78-95. PubMed ID: 27979613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapies for the bone in mucopolysaccharidoses.
    Tomatsu S; Alméciga-Díaz CJ; Montaño AM; Yabe H; Tanaka A; Dung VC; Giugliani R; Kubaski F; Mason RW; Yasuda E; Sawamoto K; Mackenzie W; Suzuki Y; Orii KE; Barrera LA; Sly WS; Orii T
    Mol Genet Metab; 2015 Feb; 114(2):94-109. PubMed ID: 25537451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orthopaedic challenges for mucopolysaccharidoses.
    Borgo A; Cossio A; Gallone D; Vittoria F; Carbone M
    Ital J Pediatr; 2018 Nov; 44(Suppl 2):123. PubMed ID: 30442173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation.
    Opoka-Winiarska V; Jurecka A; Emeryk A; Tylki-Szymańska A
    Osteoarthritis Cartilage; 2013 Dec; 21(12):1813-23. PubMed ID: 23954699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered interaction and distribution of glycosaminoglycans and growth factors in mucopolysaccharidosis type I bone disease.
    Kingma SDK; Wagemans T; IJlst L; Bronckers ALJJ; van Kuppevelt TH; Everts V; Wijburg FA; van Vlies N
    Bone; 2016 Jul; 88():92-100. PubMed ID: 27105565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth impairment and limited range of joint motion in children should raise suspicion of an attenuated form of mucopolysaccharidosis: expert opinion.
    Guffon N; Journeau P; Brassier A; Leger J; Chevallier B
    Eur J Pediatr; 2019 Apr; 178(4):593-603. PubMed ID: 30740618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone Biomarkers in Mucopolysaccharidoses.
    Nakamura-Utsunomiya A
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses.
    Kakkis E; Marsden D
    Mol Genet Metab; 2020 May; 130(1):7-15. PubMed ID: 32224020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses.
    Kubaski F; Suzuki Y; Orii K; Giugliani R; Church HJ; Mason RW; Dũng VC; Ngoc CT; Yamaguchi S; Kobayashi H; Girisha KM; Fukao T; Orii T; Tomatsu S
    Mol Genet Metab; 2017 Mar; 120(3):247-254. PubMed ID: 28065440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities.
    Wilson S; Hashamiyan S; Clarke L; Saftig P; Mort J; Dejica VM; Brömme D
    Am J Pathol; 2009 Nov; 175(5):2053-62. PubMed ID: 19834056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orthopaedic aspects of mucopolysaccharidoses.
    White KK
    Rheumatology (Oxford); 2011 Dec; 50 Suppl 5():v26-33. PubMed ID: 22210667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different?
    Węgrzyn G; Jakóbkiewicz-Banecka J; Narajczyk M; Wiśniewski A; Piotrowska E; Gabig-Cimińska M; Kloska A; Słomińska-Wojewódzka M; Korzon-Burakowska A; Węgrzyn A
    Med Hypotheses; 2010 Dec; 75(6):605-9. PubMed ID: 20732748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed hypertrophic differentiation of epiphyseal chondrocytes contributes to failed secondary ossification in mucopolysaccharidosis VII dogs.
    Peck SH; O'Donnell PJ; Kang JL; Malhotra NR; Dodge GR; Pacifici M; Shore EM; Haskins ME; Smith LJ
    Mol Genet Metab; 2015 Nov; 116(3):195-203. PubMed ID: 26422116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of Morquio A patient with tracheal obstruction from birth to death.
    Doherty C; Averill LW; Theroux M; Mackenzie WG; Pizarro C; Mason RW; Tomatsu S
    Mol Genet Metab Rep; 2018 Mar; 14():59-67. PubMed ID: 29326877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-dimensional NMR spectroscopy of urinary glycosaminoglycans from patients with different mucopolysaccharidoses.
    Hochuli M; Wüthrich K; Steinmann B
    NMR Biomed; 2003 Jun; 16(4):224-36. PubMed ID: 14558120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycosaminoglycans in mucopolysaccharidoses and other disorders.
    Khan SA; Nidhi F; Leal AF; Celik B; Herreño-Pachón AM; Saikia S; Benincore-Flórez E; Ago Y; Tomatsu S
    Adv Clin Chem; 2024; 122():1-52. PubMed ID: 39111960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses.
    Banecka-Majkutewicz Z; Jakóbkiewicz-Banecka J; Gabig-Cimińska M; Węgrzyn A; Węgrzyn G
    Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):461-8. PubMed ID: 22949095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucopolysaccharidoses.
    Cimaz R; La Torre F
    Curr Rheumatol Rep; 2014 Jan; 16(1):389. PubMed ID: 24264718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.